{"answer":{"query":"stelara","resolved_as":"name","packages":9,"applications":["BLA125261","BLA761044"],"identity":{"application_numbers":["BLA125261","BLA761044"],"marketing_categories":["BLA"],"labelers":[{"text":"JANSSEN BIOTECH, INC","untrusted":true}],"dosage_forms":[{"text":"SOLUTION","untrusted":true},{"text":"INJECTION, SOLUTION","untrusted":true}],"marketing_start":{"earliest":"2009-09-25","latest":"2025-04-01","packages_with_a_start_date":8}},"price":{"median_negotiated_over_nadac":0.301,"packages_compared":2,"packages_listed":9,"negotiated_price_ends":"2026-12-31","rows":[{"ndc":"57894005427","name":{"text":"STELARA 130 mg/26 mL (5 mg/mL)","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":25.108135,"ratio":null,"ful_per_unit":null},{"ndc":"57894006002","name":{"text":"STELARA 45MG/0.5ML","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":8979.645026,"ratio":null,"ful_per_unit":null},{"ndc":"57894006003","name":{"text":"STELARA 45MG/0.5ML - prefilled syringe","untrusted":true},"class":"B","nadac_per_unit":29874.448,"negotiated_per_unit":8979.645026,"ratio":0.301,"ful_per_unit":null},{"ndc":"57894006102","name":{"text":"","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":8980.144587,"ratio":null,"ful_per_unit":null},{"ndc":"57894006103","name":{"text":"STELARA 90MG/1.0ML - prefilled syringe","untrusted":true},"class":"B","nadac_per_unit":29792.78667,"negotiated_per_unit":8980.144587,"ratio":0.301,"ful_per_unit":null},{"ndc":"57894044001","name":{"text":"Ustekinumab 45mg/0.5mL PFS","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":8979.645026,"ratio":null,"ful_per_unit":null},{"ndc":"57894044003","name":{"text":"Ustekinumab 45mg/0.5mL Vial","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":8979.645026,"ratio":null,"ful_per_unit":null},{"ndc":"57894044101","name":{"text":"Ustekinumab 90mg/mL PFS","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":8980.144587,"ratio":null,"ful_per_unit":null},{"ndc":"57894044401","name":{"text":"Ustekinumab 130mg/26mL Vial","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":25.108135,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":null},"label_history":{"events_total":46,"non_cmc_events":46,"counts_by_class":{"LABELING":35,"EFFICACY":10,"UNKNOWN":1},"cmc_events":0,"recent_non_cmc_events":[{"application":"BLA125261","submission_no":173,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-08-28","documents":[{"type":"Letter","date":"2026-09-01","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761044Orig1s021,125261Orig1s173ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-09-01","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125261s173lbl.pdf","untrusted":true}}],"fact_id":"b652338157f9f23b70648a6c"},{"application":"BLA761044","submission_no":21,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2026-08-28","documents":[{"type":"Letter","date":"2026-09-01","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761044Orig1s021,125261Orig1s173ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-09-01","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761044s021lbl.pdf","untrusted":true}}],"fact_id":"414f1d2097129cece80d6869"},{"application":"BLA125261","submission_no":174,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-07-15","documents":[{"type":"Letter","date":"2026-07-16","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/125261Orig1s174ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-07-29","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125261s174lbl.pdf","untrusted":true}}],"fact_id":"c1a827652160734d180883c0"},{"application":"BLA761044","submission_no":22,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-07-15","documents":[],"fact_id":"032b01b884cde903a3e9adcf"},{"application":"BLA125261","submission_no":172,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-04-15","documents":[{"type":"Letter","date":"2026-04-16","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761044Orig1s020, 125261Orig1s172ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-04-20","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761044Orig1s020, 125261Orig1s172lbl.pdf","untrusted":true}}],"fact_id":"b1fb2f4a707f705487a20aa4"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":3,"te_code_counts":{"NOT_PROVIDED":3},"marketing_status_counts":{"Prescription":3},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"BLA125261","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"STELARA","untrusted":true},"form":{"text":"INJECTABLE; INJECTION","untrusted":true},"strength":{"text":"45MG/0.5ML","untrusted":true}},{"application":"BLA125261","product_no":"002","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"STELARA","untrusted":true},"form":{"text":"INJECTABLE; INJECTION","untrusted":true},"strength":{"text":"90MG/1ML","untrusted":true}},{"application":"BLA761044","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"STELARA","untrusted":true},"form":{"text":"INJECTABLE;INJECTION","untrusted":true},"strength":{"text":"130MG/26ML","untrusted":true}}]},"recalls":{"recalls_total":1,"counts_by_class":{"Class II":1},"packages_of_these_applications":8,"most_recent":[{"recall_number":"D-0762-2018","classification":"Class II","status":"Terminated","report_date":"2018-05-16","recall_initiated":"2018-04-03","recalling_firm":{"text":"Kroger Specialty Pharmacy, Inc.","untrusted":true},"reason":{"text":"Lack of Processing Controls.","untrusted":true},"packages_named":1,"fact_id":"14af95e29f095100dcbdc65e"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"supply":{"fda_shortage_status_counts":{},"packages_with_a_termination_date":1,"next_package_termination_dates":[],"packages_with_future_termination_date":0,"termination_meaning":"manufacturer-reported last-lot expiry or withdrawal date of one package; other packages and generics can remain"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"USTEKINUMAB","untrusted":true},"recruiting_interventional_count":17,"not_yet_recruiting_count":6,"by_phase":{"PHASE4":7,"PHASE1/PHASE2":1,"PHASE3":2,"PHASE2":4,"NA":2,"PHASE1":1},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT07310095","title":{"text":"A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"Xian-Janssen Pharmaceutical Ltd.","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-03","start_date":"2025-12-30","link":{"text":"https://clinicaltrials.gov/study/NCT07310095","untrusted":true}},{"nct_id":"NCT03167437","title":{"text":"An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"National Institute of Allergy and Infectious Diseases (NIAID)","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-02","start_date":"2017-10-30","link":{"text":"https://clinicaltrials.gov/study/NCT03167437","untrusted":true}},{"nct_id":"NCT07116967","title":{"text":"Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Bristol-Myers Squibb","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-28","start_date":"2025-09-22","link":{"text":"https://clinicaltrials.gov/study/NCT07116967","untrusted":true}},{"nct_id":"NCT05928039","title":{"text":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"University of Calgary","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-26","start_date":"2023-10-25","link":{"text":"https://clinicaltrials.gov/study/NCT05928039","untrusted":true}},{"nct_id":"NCT06807593","title":{"text":"Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"M.D. Anderson Cancer Center","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-09-14","start_date":"2026-02-24","link":{"text":"https://clinicaltrials.gov/study/NCT06807593","untrusted":true}}],"fact_id":"cb28fcdaa01602b827998f24"}]},"assistance_and_offers":{"programs_listing_this_drug":[{"name":{"text":"Johnson & Johnson Patient Assistance Program","untrusted":true},"type":"manufacturer","url":"https://www.jnjwithme.com/","status":null,"needs_status_check":false,"has_offer":false}],"manufacturer_offers":[{"program":"stelara-savings-program","kind":"copay_card","price_figures":{"payAsLittleAsPerDose":5},"conditions":{"text":"The page states the program is for patients using commercial or private insurance, a maximum program benefit per calendar year applies (amount not stated in the text read), there may be a savings limit per dose, and terms expire at the end of each calendar year and may change.","untrusted":true},"limited_time":false,"expires_note":{"text":"Terms expire at the end of each calendar year and may change","untrusted":true},"stated_end_date":null,"expired":false,"detail":{"text":"The J&J withMe Stelara page states pay as little as $5 per dose for patients using commercial or private insurance. A maximum program benefit per calendar year applies but the amount is not stated in the text read; terms expire at the end of each calendar year and may change.","untrusted":true},"read_on":"2026-11-07T07:23:55.567Z","source_url":"https://www.jnjwithme.com/patient/stelara/cost-support","proof_state":"verified","fact_id":"001eca6172fe94bf53613978"}],"note":"A program that lists a drug has not decided anything about any person: each program decides who qualifies, and a status other than open means it may not take new patients. Offers change and expire; read each offer's source and stated end date. A price figure is what the page states, not a quote."},"spending":{"reported_under":{"generic":{"text":"Ustekinumab","untrusted":true},"brand":{"text":"Stelara*","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":1106356248.4,"claims":53677,"beneficiaries":12914,"average_spending_per_claim_usd":20611.365174,"fact_id":"a64800f303a176505beca1ef"},{"year":2021,"gross_spending_usd":1567482458.4,"claims":70502,"beneficiaries":16156,"average_spending_per_claim_usd":22233.163008,"fact_id":"d37c03cd345a5c0d4dd96ecf"},{"year":2022,"gross_spending_usd":2339082716,"claims":96974,"beneficiaries":19969,"average_spending_per_claim_usd":24120.720152,"fact_id":"d8cdc2597860330da2181c5b"},{"year":2023,"gross_spending_usd":2987778599.9,"claims":117068,"beneficiaries":22930,"average_spending_per_claim_usd":25521.736084,"fact_id":"4fd47bd6f284aa889db56d3b"},{"year":2024,"gross_spending_usd":3378017374.1,"claims":132865,"beneficiaries":24754,"average_spending_per_claim_usd":25424.433629,"fact_id":"59bc3d536e097941fe1ceb44"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"biologic_status":{"products":[{"application":"BLA125261","status":"Reference","name":{"text":"Stelara","untrusted":true},"proper_name":{"text":"ustekinumab","untrusted":true},"license_status":"Licensed","approval_date":"2009-09-25","reference_product":null,"interchangeable_date":null,"biosimilars_listed":0,"interchangeables_listed":10,"biosimilars":[],"interchangeables":[{"name":{"text":"Wezlana","untrusted":true},"proper_name":{"text":"ustekinumab-auub","untrusted":true},"bla_number":"761285","approval_date":"2023-10-31","interchangeable_date":"2023-10-31"},{"name":{"text":"Wezlana","untrusted":true},"proper_name":{"text":"ustekinumab-auub","untrusted":true},"bla_number":"761331","approval_date":"2023-10-31","interchangeable_date":"2023-10-31"},{"name":{"text":"Steqeyma","untrusted":true},"proper_name":{"text":"ustekinumab-stba","untrusted":true},"bla_number":"761338","approval_date":"2024-12-17","interchangeable_date":"2025-04-30"},{"name":{"text":"Selarsdi","untrusted":true},"proper_name":{"text":"ustekinumab-aekn","untrusted":true},"bla_number":"761343","approval_date":"2024-04-16","interchangeable_date":"2025-04-30"},{"name":{"text":"Imuldosa","untrusted":true},"proper_name":{"text":"ustekinumab-srlf","untrusted":true},"bla_number":"761364","approval_date":"2024-10-10","interchangeable_date":"2026-06-05"},{"name":{"text":"Pyzchiva","untrusted":true},"proper_name":{"text":"ustekinumab-ttwe","untrusted":true},"bla_number":"761373","approval_date":"2024-06-28","interchangeable_date":"2025-04-30"},{"name":{"text":"Otulfi","untrusted":true},"proper_name":{"text":"ustekinumab-aauz","untrusted":true},"bla_number":"761379","approval_date":"2024-09-27","interchangeable_date":"2025-04-30"},{"name":{"text":"Yesintek","untrusted":true},"proper_name":{"text":"ustekinumab-kfce","untrusted":true},"bla_number":"761406","approval_date":"2024-11-29","interchangeable_date":"2025-04-30"},{"name":{"text":"Starjemza","untrusted":true},"proper_name":{"text":"ustekinumab-hmny","untrusted":true},"bla_number":"761419","approval_date":"2025-05-22","interchangeable_date":"2025-05-22"},{"name":{"text":"Pyzchiva","untrusted":true},"proper_name":{"text":"ustekinumab-ttwe","untrusted":true},"bla_number":"761425","approval_date":"2024-06-28","interchangeable_date":"2025-04-30"}],"purple_book_version":"purplebook-2026-10","read_on":"2026-11-07T07:33:31.186Z","fact_id":"5a0e1ed0c441ab57516c0523"},{"application":"BLA761044","status":"Reference","name":{"text":"Stelara","untrusted":true},"proper_name":{"text":"ustekinumab","untrusted":true},"license_status":"Licensed","approval_date":"2016-09-23","reference_product":null,"interchangeable_date":null,"biosimilars_listed":0,"interchangeables_listed":10,"biosimilars":[],"interchangeables":[{"name":{"text":"Wezlana","untrusted":true},"proper_name":{"text":"ustekinumab-auub","untrusted":true},"bla_number":"761285","approval_date":"2023-10-31","interchangeable_date":"2023-10-31"},{"name":{"text":"Wezlana","untrusted":true},"proper_name":{"text":"ustekinumab-auub","untrusted":true},"bla_number":"761331","approval_date":"2023-10-31","interchangeable_date":"2023-10-31"},{"name":{"text":"Steqeyma","untrusted":true},"proper_name":{"text":"ustekinumab-stba","untrusted":true},"bla_number":"761338","approval_date":"2024-12-17","interchangeable_date":"2025-04-30"},{"name":{"text":"Selarsdi","untrusted":true},"proper_name":{"text":"ustekinumab-aekn","untrusted":true},"bla_number":"761343","approval_date":"2024-04-16","interchangeable_date":"2025-04-30"},{"name":{"text":"Imuldosa","untrusted":true},"proper_name":{"text":"ustekinumab-srlf","untrusted":true},"bla_number":"761364","approval_date":"2024-10-10","interchangeable_date":"2026-06-05"},{"name":{"text":"Pyzchiva","untrusted":true},"proper_name":{"text":"ustekinumab-ttwe","untrusted":true},"bla_number":"761373","approval_date":"2024-06-28","interchangeable_date":"2025-04-30"},{"name":{"text":"Otulfi","untrusted":true},"proper_name":{"text":"ustekinumab-aauz","untrusted":true},"bla_number":"761379","approval_date":"2024-09-27","interchangeable_date":"2025-04-30"},{"name":{"text":"Yesintek","untrusted":true},"proper_name":{"text":"ustekinumab-kfce","untrusted":true},"bla_number":"761406","approval_date":"2024-11-29","interchangeable_date":"2025-04-30"},{"name":{"text":"Starjemza","untrusted":true},"proper_name":{"text":"ustekinumab-hmny","untrusted":true},"bla_number":"761419","approval_date":"2025-05-22","interchangeable_date":"2025-05-22"},{"name":{"text":"Pyzchiva","untrusted":true},"proper_name":{"text":"ustekinumab-ttwe","untrusted":true},"bla_number":"761425","approval_date":"2024-06-28","interchangeable_date":"2025-04-30"}],"purple_book_version":"purplebook-2026-10","read_on":"2026-11-07T07:33:31.186Z","fact_id":"9d732ddb3f401d775357d908"}],"reading":"what the FDA Purple Book lists on its read date, a record and not a forecast of launch or substitution"},"payment_limit":{"codes":[{"hcpcs":"J3358","quarter":"2026Q4","effective":"October 1, 2026 through December 31, 2026","payment_limit_usd":10.249,"dosage_descriptor":{"text":"1 MG","untrusted":true},"packages_matched":2,"read_on":"2026-11-07T07:31:28.000Z","source_url":{"text":"https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files","untrusted":true},"fact_id":"14612305c2a32d69967482fb"}],"codes_total":1,"meaning":"a Medicare Part B payment ceiling for providers billing a HCPCS code, per dosage descriptor unit; not a price a patient pays, and the presence of a code does not indicate that Medicare covers a product"},"rems":{"programs":[{"application":"BLA125261","program":{"text":"Stelara","untrusted":true},"rems_id":"50","in_force":false,"released":true,"moved_to_shared_system":false,"has_etasu":false,"program_date":"2009-09-25","last_modified":"2017-02-15","source_page":"https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=50","other_programs":0,"read_on":"2026-11-07T20:05:28.959Z","fact_id":"5168436fc10288549cede964"}],"reading":"what the FDA REMS@FDA files tie to the application on the read date; it does not say which prescribers or pharmacies take part or whether a patient needs the program"},"orphan_designation":{"ingredients":[{"ingredient":{"text":"ustekinumab","untrusted":true},"designation_count":5,"approved_count":2,"recent":[{"designated":"2017-07-18","use":{"text":"Treatment of pediatric systemic lupus erythematosus","untrusted":true},"status":"Designated/Designation Withdrawn or Revoked","sponsor":{"text":"Janssen Biotech, Inc.","untrusted":true},"approved":false},{"designated":"2017-02-22","use":{"text":"Treatment of pediatric ulcerative colitis","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Janssen Biotech, Inc.","untrusted":true},"approved":true},{"designated":"2016-05-18","use":{"text":"Treatment of pediatric Crohn's disease (0 through 16 years of age)","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Janssen Research & Development, LLC","untrusted":true},"approved":true},{"designated":"2011-12-28","use":{"text":"Treatment of chronic sarcoidosis","untrusted":true},"status":"Designated/Designation Withdrawn or Revoked","sponsor":{"text":"Janssen Biotech, Inc.","untrusted":true},"approved":false},{"designated":"2010-11-29","use":{"text":"Treatment of type 1 diabetes mellitus patients with residual beta-cell function.","untrusted":true},"status":"Designated/Designation Withdrawn or Revoked","sponsor":{"text":"Johnson & Johnson Pharmaceutical & Development LLC","untrusted":true},"approved":false}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"fb88813b51c366a5c098de89"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"},"medicaid_state_utilization":{"year":2025,"states_with_data":2,"all_states_medicaid_reimbursed_usd":1563268.48,"all_states_medicaid_paid_prescriptions":113,"top_states":[{"state":"IA","medicaid_paid_prescriptions":66,"medicaid_reimbursed_usd":917598.87,"total_reimbursed_usd":917598.87,"packages":1,"covers":"all_record_types","fact_id":"7e8805ed91400b560b5afeb5"},{"state":"MO","medicaid_paid_prescriptions":47,"medicaid_reimbursed_usd":645669.61,"total_reimbursed_usd":645669.61,"packages":1,"covers":"all_record_types","fact_id":"66846c909f1c129ca58e714b"}],"unlabelled_state_code_xx":null,"built_from_facts":2,"facts_fee_for_service_only":0,"older_year_facts_not_used":110,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"b2618d01d312da62aceb1691","field":"ndc.listing","entity":"ndc:57894005427"},{"fact_id":"cbab17ec093e41cde3ee8f79","field":"ndc.listing","entity":"ndc:57894006002"},{"fact_id":"b5cb89869387f416f74ef1d3","field":"ndc.listing","entity":"ndc:57894006003"},{"fact_id":"13541f67edfc93bdf2836b12","field":"ndc.nadac_price","entity":"ndc:57894006003"},{"fact_id":"50ec472dae8d03807072ee4e","field":"ndc.mfp","entity":"ndc:57894005427"},{"fact_id":"6ee318c4ee793a719286bba0","field":"ndc.mfp","entity":"ndc:57894006002"},{"fact_id":"00025c1e499a3f749c66eea6","field":"ndc.mfp","entity":"ndc:57894006003"},{"fact_id":"b652338157f9f23b70648a6c","field":"drug.label_event","entity":"application:BLA125261"},{"fact_id":"414f1d2097129cece80d6869","field":"drug.label_event","entity":"application:BLA761044"},{"fact_id":"c1a827652160734d180883c0","field":"drug.label_event","entity":"application:BLA125261"},{"fact_id":"032b01b884cde903a3e9adcf","field":"drug.label_event","entity":"application:BLA761044"},{"fact_id":"b1fb2f4a707f705487a20aa4","field":"drug.label_event","entity":"application:BLA125261"},{"fact_id":"96f746c15ad01c433386dcb6","field":"drug.marketing_status","entity":"application:BLA125261"},{"fact_id":"3f062551c85d177dbfa2cb1f","field":"drug.marketing_status","entity":"application:BLA125261"},{"fact_id":"e9e80a1c4ac9e662c19ec598","field":"drug.marketing_status","entity":"application:BLA761044"},{"fact_id":"14af95e29f095100dcbdc65e","field":"ndc.recall","entity":"ndc:57894006103"},{"fact_id":"cb28fcdaa01602b827998f24","field":"drug.trial_access","entity":"drug:ustekinumab"},{"fact_id":"001eca6172fe94bf53613978","field":"program.offer","entity":"program:stelara-savings-program"},{"fact_id":"a64800f303a176505beca1ef","field":"drug.partd_spending","entity":"drug:ustekinumab|stelara"},{"fact_id":"d37c03cd345a5c0d4dd96ecf","field":"drug.partd_spending","entity":"drug:ustekinumab|stelara"},{"fact_id":"d8cdc2597860330da2181c5b","field":"drug.partd_spending","entity":"drug:ustekinumab|stelara"},{"fact_id":"4fd47bd6f284aa889db56d3b","field":"drug.partd_spending","entity":"drug:ustekinumab|stelara"},{"fact_id":"59bc3d536e097941fe1ceb44","field":"drug.partd_spending","entity":"drug:ustekinumab|stelara"},{"fact_id":"5a0e1ed0c441ab57516c0523","field":"drug.biologic_status","entity":"application:BLA125261"},{"fact_id":"c5fc508780ee24fd44732c7f","field":"drug.biologic_status","entity":"application:BLA761285"},{"fact_id":"ec9c5c9f4a51e203d3b46f5e","field":"drug.biologic_status","entity":"application:BLA761331"},{"fact_id":"89e634dc9e75c5360ac5b4b9","field":"drug.biologic_status","entity":"application:BLA761338"},{"fact_id":"d980a30f82ee12b36288bd83","field":"drug.biologic_status","entity":"application:BLA761343"},{"fact_id":"72d4f97b8585aae094eeae81","field":"drug.biologic_status","entity":"application:BLA761364"},{"fact_id":"e97060c9d0295a043b0304ab","field":"drug.biologic_status","entity":"application:BLA761373"},{"fact_id":"75e21cebcaab307b019cdf60","field":"drug.biologic_status","entity":"application:BLA761379"},{"fact_id":"d367e555eeed9ac172999f3e","field":"drug.biologic_status","entity":"application:BLA761406"},{"fact_id":"f74bdffac919d368433bf6da","field":"drug.biologic_status","entity":"application:BLA761419"},{"fact_id":"dc02e5c2b74d47987d806d6d","field":"drug.biologic_status","entity":"application:BLA761425"},{"fact_id":"9d732ddb3f401d775357d908","field":"drug.biologic_status","entity":"application:BLA761044"},{"fact_id":"14612305c2a32d69967482fb","field":"drug.asp_price","entity":"hcpcs:J3358"},{"fact_id":"5168436fc10288549cede964","field":"drug.rems","entity":"application:BLA125261"},{"fact_id":"fb88813b51c366a5c098de89","field":"drug.orphan_designation","entity":"drug:ustekinumab"},{"fact_id":"7e8805ed91400b560b5afeb5","field":"ndc.medicaid_state_utilization","entity":"ndc_state:57894006003:IA"},{"fact_id":"66846c909f1c129ca58e714b","field":"ndc.medicaid_state_utilization","entity":"ndc_state:57894006003:MO"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"generic_entry:BLA125261","reason":"no generic-entry fact for this application: no patent or exclusivity is listed for it in the Orange Book edition read, so no date is stated"},{"code":"NO_DATA","field":"generic_entry:BLA761044","reason":"no generic-entry fact for this application: no patent or exclusivity is listed for it in the Orange Book edition read, so no date is stated"},{"code":"NO_DATA","field":"generic_entry","reason":"no application of this drug has a generic-entry fact; no date is stated"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}